Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RATIONALE-312: Tislelizumab in ES-SCLC
NCT04005716Phase 3Completed
- Sponsor
- BeiGene
- Start
- Jul 2019
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Tislelizumab + Chemotherapy with Placebo + Chemotherapy (2 arms). Primary endpoint: Overall Survival up to 45 months. Started Jul 2019; status: completed.
02
Drugs
tislelizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04005716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04005716.